Keeping Track: Vertex’ Trikafta Speeds To US Approval; New Indications For AZ’s Farxiga, J&J’s Stelara, GSK’s Zejula

 
• By Bridget Silverman

The latest drug development news and highlights from our US FDA Performance Trackers.

Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers